10 drugs to watch
Published Updated
1 Min Read
For reprint and licensing requests for this article, click here.
More From Employee Benefit News
The compliance risks to watch out for this back-to-school season
Establishing policies that help with stressors like commuting logistics and finding after-school care can avoid disruption of in-office expectations.
Q&A: Aflac’s Matthew Owenby is watching burnout closely
The 2026 Excellence in Benefits winner is leading the insurance company's efforts to close the preventative care gap and personalize the employee experience.
Employers face a new GLP-1 question: Are the drugs worth it?
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
What Trump’s ‘Great Healthcare Plan’ means for drug costs and price transparency
The legislation calls on Congress to lower prescription drug costs, shift subsidies directly to consumers, and enforce strict price transparency.
Benefits Think What brokers should watch in claims data sharing
The practical takeaway is to treat data-sharing requests as a risk-allocation exercise, not just an operational convenience.
